🔎 Trials Near Me

Home › Myeloproliferative Neoplasms › North Carolina

Myeloproliferative Neoplasms clinical trials in North Carolina

13 studies for Myeloproliferative Neoplasms are looking for participants at sites in North Carolina.

Cities in North Carolina

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • and 1 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406

Project: Every Child for Younger Patients With Cancer

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • and 4 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  • University of North Carolina At Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • University of North Carolina At Chapel Hill, Chapel Hill
  • Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694

Evaluation of the Pathobiology of CALR-mutated MPN Cells

  • Atrium Health Levine Cancer, Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT06480591

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • Wake Forest Baptist Medical Center, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chapel Hill
  • Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.